image
Healthcare - Medical - Devices - NASDAQ - US
$ 5.67
-2.07 %
$ 202 M
Market Cap
-11.34
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one MGRM stock under the worst case scenario is HIDDEN Compared to the current market price of 5.67 USD, Monogram Orthopaedics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one MGRM stock under the base case scenario is HIDDEN Compared to the current market price of 5.67 USD, Monogram Orthopaedics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one MGRM stock under the best case scenario is HIDDEN Compared to the current market price of 5.67 USD, Monogram Orthopaedics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MGRM

image
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
0 REVENUE
0.00%
-15.3 M OPERATING INCOME
11.34%
-16.3 M NET INCOME
-18.79%
-14 M OPERATING CASH FLOW
-3.14%
-84 K INVESTING CASH FLOW
-29.40%
16.1 M FINANCING CASH FLOW
-3.63%
0 REVENUE
0.00%
-3.33 M OPERATING INCOME
-14.21%
-3.19 M NET INCOME
24.98%
-2.31 M OPERATING CASH FLOW
22.89%
-156 K INVESTING CASH FLOW
-331.05%
82 K FINANCING CASH FLOW
-96.15%
Balance Sheet Monogram Orthopaedics, Inc.
image
Current Assets 16.3 M
Cash & Short-Term Investments 15.7 M
Receivables 0
Other Current Assets 625 K
Non-Current Assets 1.49 M
Long-Term Investments 0
PP&E 338 K
Other Non-Current Assets 1.15 M
88.11 %3.52 %6.47 %Total Assets$17.8m
Current Liabilities 1.54 M
Accounts Payable 1.17 M
Short-Term Debt 138 K
Other Current Liabilities 229 K
Non-Current Liabilities 1.73 M
Long-Term Debt 226 K
Other Non-Current Liabilities 1.5 M
35.94 %4.22 %7.01 %6.92 %45.91 %Total Liabilities$3.3m
EFFICIENCY
Earnings Waterfall Monogram Orthopaedics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 15.3 M
Operating Income -15.3 M
Other Expenses 1.02 M
Net Income -16.3 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)000(15m)(15m)(1m)(16m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-112.58% ROE
-112.58%
-91.89% ROA
-91.89%
-93.54% ROIC
-93.54%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Monogram Orthopaedics, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -16.3 M
Depreciation & Amortization 430 K
Capital Expenditures -84 K
Stock-Based Compensation 1.17 M
Change in Working Capital -839 K
Others 1.68 M
Free Cash Flow -14.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Monogram Orthopaedics, Inc.
image
Wall Street analysts predict an average 1-year price target for MGRM of $5.4 , with forecasts ranging from a low of $5.4 to a high of $5.4 .
MGRM Lowest Price Target Wall Street Target
5.4 USD -4.76%
MGRM Average Price Target Wall Street Target
5.4 USD -4.76%
MGRM Highest Price Target Wall Street Target
5.4 USD -4.76%
Price
Max Price Target
Min Price Target
Average Price Target
66665555444433332222Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Monogram Orthopaedics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
MONOGRAM TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Monogram Technologies Inc. - MGRM NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Monogram Technologies Inc. (NasdaqCM: MGRM) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Monogram will receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive u. businesswire.com - 6 days ago
MGRM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Monogram Technologies to Zimmer Biomet MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) --  The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. globenewswire.com - 1 week ago
Shareholder Alert: The Ademi Firm Investigates Whether Monogram Technologies Inc. is Obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Monogram (NASDAQ: MGRM) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Monogram will receive $4.04 per share in cash, representing an equity value of appro. businesswire.com - 1 week ago
MGRM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Monogram Technologies Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Monogram Technologies Inc. (NASDAQ: MGRM) to Zimmer Biomet Holdings, Inc. is fair to Monogram shareholders. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development. businesswire.com - 1 week ago
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Indiana and AUSTIN, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ: MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030. globenewswire.com - 1 week ago
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Proposed transaction creates the  broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs  Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas , July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ: MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. prnewswire.com - 1 week ago
Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced the mandatory conversion of all outstanding shares of 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") that were issued in connection with the Company's offering that closed on October 1, 2024 (the "Offering"). During the Offering, the Company issued and sold units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"). accessnewswire.com - 2 weeks ago
Monogram Technologies Inc. (MGRM) Q1 2025 Earnings Call Transcript Monogram Technologies Inc. (NASDAQ:MGRM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Noel Knape - Chief Financial Officer Ben Sexson - Chief Executive Officer Conference Call Participants Jason Wittes - ROTH Capital Tom Kerr - Zacks Larry Holub Good afternoon, everyone, and welcome to the Monogram Technologies First Quarter 2025 Financial Results and Business Update Conference Call. A question-and-answer session will follow the formal presentation. seekingalpha.com - 2 months ago
Monogram Technologies Reports First Quarter 2025 Financial Results Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. globenewswire.com - 2 months ago
Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESS Newswire / May 6, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones. accessnewswire.com - 2 months ago
CORRECTION FROM SOURCE: Monogram Technologies Receives Regulatory Approval to Start Clinical Trials in India Monogram Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation Patient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System AUSTIN, TX / ACCESS Newswire / April 29, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced it has obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The study will be conducted in collaboration with Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups. accessnewswire.com - 2 months ago
Monogram Technologies Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation in India Patient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System AUSTIN, TEXAS / ACCESS Newswire / April 29, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced it has obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The study will be conducted in collaboration with Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups. accessnewswire.com - 2 months ago
8. Profile Summary

Monogram Orthopaedics, Inc. MGRM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 202 M
Dividend Yield 0.00%
Description Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Contact 3913 Todd Lane, Austin, TX, 78744 https://www.monogramorthopedics.com
IPO Date May 18, 2023
Employees 27
Officers Mr. Noel Knape CPA, M.B.A. Chief Financial Officer Dr. Kamran Shamaei Ph.D. Chief Technology Officer Chris Tyson Executive Vice President - MZ North America Dr. Douglas Unis Founder, Chief Medical Officer & Director Mr. Benjamin Sexson C.F.A. Chairman of the Board, President & Chief Executive Officer